June 7, 2022
Update: Nordea mandated for IPO of KKR-backed Nordic Bioscience, a developer of non-invasive biomarkers - situation first and exclusively covered by NKP M&A Insights on 11 April, process to kick off in the fall of 2022 (NKP Proprietary)
NKP | M&A Insights Proprietary
Headline from pre-deal coverage in M&A Insights